Key Takeaways
- Benchmark for Innovation: Natural history studies track disease progression without intervention, providing essential benchmarks for measuring new treatment effectiveness.
- Rare Disease Impact: These studies are critical for rare diseases, helping to identify subtypes, design clinical trials, and secure regulatory approval.
- AI-Enhanced Data: AI and wearables enable continuous, real-time health monitoring, replacing periodic assessments with a comprehensive data stream.
- Predictive Insights: Machine learning algorithms identify patterns in complex datasets to forecast disease progression and improve patient recruitment.
- Regulatory Support: The FDA provides specific guidelines for using natural history data as real-world evidence in drug development.
What are natural history studies?
A natural history study is a preplanned observational study designed to track the course of a disease over time. Its purpose is to identify demographic, genetic, environmental, and other variables that correlate with the disease's development and outcomes. Traditionally, the "natural history" of a disease refers to its progression in the absence of intervention, from onset until resolution or end of life. In practice, most natural history studies include patients receiving the current standard of care or emergent treatment, which may alter some manifestations of the disease. Fully untreated populations are rare, both for ethical reasons and because most patients will have received some form of care prior to enrollment.
Natural history studies aim to capture various factors, including demographic, genetic, and environmental variables, that correlate with disease development and outcomes. It is worth distinguishing these studies from patient registries, which are organized systems for collecting and storing information about people with a disease. While registries tend to be broad in scope, natural history studies have a more specific goal: tracking how a disease progresses over a defined period. Some registries do function as natural history studies, depending on the depth and structure of the data they collect, but the two are not interchangeable.
Natural history studies are vital for a few key reasons:
- Understanding disease progression: Rare diseases often have limited research; these studies provide insights essential for management strategies.
- Identifying variability and subtypes: Researchers can identify different subtypes, leading to personalized treatment approaches.
- Designing clinical trials: Data informs trial design, outcome measures, and patient selection criteria.
- Improving patient care: Helps providers anticipate symptoms and improve quality of life.
- Regulatory approval: Demonstrates drug safety and effectiveness, often required for FDA approval.
Study design considerations: Natural history studies can be retrospective, prospective, or both. Retrospective studies draw on pre-existing data, such as medical records, to reconstruct a patient's disease trajectory. Prospective studies collect new data from patients over a defined period. Many studies combine both approaches, using historical records to establish baseline context while collecting new observations going forward. The choice of design has direct implications for data quality, regulatory utility, and the operational demands placed on sites and participants.
Regulatory authorities are recognizing the value of real-world evidence, and natural history studies are gaining prominence in drug development. The U.S. Food and Drug Administration (FDA) has issued draft guidance specifically addressing the use of natural history study data in rare disease drug development. The guidance notes that natural history information is usually not available or is incomplete for most rare diseases, making these studies particularly important. It emphasizes four key areas:
- Patient population: Understanding the variability in diseases related to genotypes and/or phenotypes.
- Clinical outcome assessments: Using natural history data to validate new or existing assessments in detecting disease progression, including clinic-reported, observer-reported, patient-reported, and performance outcomes.
- Development of biomarkers: Leveraging studies for biomarker strategies that can diagnose diseases, predict disease courses, and guide treatment responses.
- Use of study data: Encouraging the creation of external control arms from patient registries or natural history studies.
How AI supports data collection and analysis in natural history studies
Natural history studies generate heterogeneous data across multiple sites, time points, and collection methods. Managing this complexity manually introduces delays, inconsistencies, and gaps in analysis. AI is being applied across several areas to address these challenges:
- Enhanced data collection: Wearables and apps enable real-time tracking of heart rate, glucose, and behavior.
- Sophisticated data analysis: Machine learning uncovers patterns and biomarkers missed by human researchers.
- Predictive modelling: Forecasts complications and identifies high-risk patients for tailored interventions.
- Patient recruitment: AI scans EHRs to quickly identify diverse and accurate participant pools.
- Engagement and compliance: Chatbots provide reminders and support to improve study adherence.
- Real-time monitoring: Immediate flagging of condition changes allows for timely medical intervention.
- Data standardisation: AI integrates diverse data sources for consistency in multi-centre studies.
Across these areas, AI introduces capabilities that complement traditional research methods: faster pattern recognition, more consistent data handling, and the ability to work across larger and more diverse datasets. Its role in natural history studies is still evolving, but the practical applications are already visible in how studies are designed, monitored, and analyzed.
Conclusion
Natural history studies remain one of the most important tools for understanding disease progression, particularly in rare diseases where baseline data is limited. As the FDA has emphasized, well-designed natural history studies directly support the development of safe and effective therapies by establishing the evidence base needed for regulatory submissions.
AI is beginning to reshape how these studies are conducted, from improving data collection and standardization to enabling more sophisticated analysis across geographically dispersed populations. The practical impact is not speculative. It is visible in how study teams manage complexity, identify patterns, and generate actionable insights from longitudinal datasets.
For sponsors running precision medicine programs, the challenge is not simply collecting more data. It is building the infrastructure to collect, integrate, and act on that data across the full patient journey. Natural history studies are often the first step in that process, and how they are designed determines what is possible downstream.
To explore how Sano supports sponsors in designing and executing natural history studies, from patient finding and engagement to long-term data collection and recontact, get in touch.